NodThera grabs $40 mln Series A
UK-based NodThera, a developer of next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation, has raised $40 million in Series A funding. Sofinnova Partners and 5AM Ventures led the round with participation from Epidarex Capital and F-Prime Capital Partners.
25 June 2018•1 min read
